Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:151274975" > Simultaneous Onset ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04828naa a2201153 4500 | |
001 | oai:prod.swepub.kib.ki.se:151274975 | |
003 | SwePub | |
008 | 240701s2022 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1512749752 URI |
024 | 7 | a https://doi.org/10.3390/cancers142255302 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Cattaneo, C4 aut |
245 | 1 0 | a Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey |
264 | c 2022-11-10 | |
264 | 1 | b MDPI AG,c 2022 |
520 | a Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy. | |
700 | 1 | a Salmanton-Garcia, J4 aut |
700 | 1 | a Marchesi, F4 aut |
700 | 1 | a El-Ashwah, S4 aut |
700 | 1 | a Itri, F4 aut |
700 | 1 | a Weinbergerova, B4 aut |
700 | 1 | a Da Silva, MG4 aut |
700 | 1 | a Dargenio, M4 aut |
700 | 1 | a Davila-Valls, J4 aut |
700 | 1 | a Martin-Perez, S4 aut |
700 | 1 | a Farina, F4 aut |
700 | 1 | a Van Doesum, J4 aut |
700 | 1 | a Valkovic, T4 aut |
700 | 1 | a Besson, C4 aut |
700 | 1 | a Poulsen, CB4 aut |
700 | 1 | a Lopez-Garcia, A4 aut |
700 | 1 | a Zak, P4 aut |
700 | 1 | a Schonlein, M4 aut |
700 | 1 | a Piukovics, K4 aut |
700 | 1 | a Jaksic, O4 aut |
700 | 1 | a Cabirta, A4 aut |
700 | 1 | a Ali, N4 aut |
700 | 1 | a Sili, U4 aut |
700 | 1 | a Fracchiolla, N4 aut |
700 | 1 | a Dragonetti, G4 aut |
700 | 1 | a Adzic-Vukicevic, T4 aut |
700 | 1 | a Marchetti, M4 aut |
700 | 1 | a Machado, M4 aut |
700 | 1 | a Glenthoj, A4 aut |
700 | 1 | a Finizio, O4 aut |
700 | 1 | a Demirkan, F4 aut |
700 | 1 | a Blennow, Ou Karolinska Institutet4 aut |
700 | 1 | a Tisi, MC4 aut |
700 | 1 | a Omrani, AS4 aut |
700 | 1 | a Navratil, M4 aut |
700 | 1 | a Racil, Z4 aut |
700 | 1 | a Novak, J4 aut |
700 | 1 | a Magliano, G4 aut |
700 | 1 | a Jimenez, M4 aut |
700 | 1 | a Garcia-Vidal, C4 aut |
700 | 1 | a Erben, N4 aut |
700 | 1 | a Del Principe, MI4 aut |
700 | 1 | a Buquicchio, C4 aut |
700 | 1 | a Bergantim, R4 aut |
700 | 1 | a Batinic, J4 aut |
700 | 1 | a Al-Khabori, M4 aut |
700 | 1 | a Verga, L4 aut |
700 | 1 | a Szotkowski, T4 aut |
700 | 1 | a Samarkos, M4 aut |
700 | 1 | a Ormazabal-Velez, I4 aut |
700 | 1 | a Meers, S4 aut |
700 | 1 | a Maertens, J4 aut |
700 | 1 | a Pinczes, LI4 aut |
700 | 1 | a Hoenigl, M4 aut |
700 | 1 | a Drgona, L4 aut |
700 | 1 | a Cuccaro, A4 aut |
700 | 1 | a Bilgin, YM4 aut |
700 | 1 | a Aujayeb, A4 aut |
700 | 1 | a Rahimli, L4 aut |
700 | 1 | a Grafe, S4 aut |
700 | 1 | a Sciume, M4 aut |
700 | 1 | a Mladenovic, M4 aut |
700 | 1 | a Colak, GM4 aut |
700 | 1 | a Sacchi, MV4 aut |
700 | 1 | a Nordlander, Au Karolinska Institutet4 aut |
700 | 1 | a Venemyr, CB4 aut |
700 | 1 | a Hanakova, M4 aut |
700 | 1 | a Garcia-Pouton, N4 aut |
700 | 1 | a Emarah, Z4 aut |
700 | 1 | a Zambrotta, GPM4 aut |
700 | 1 | a Rodrigues, RN4 aut |
700 | 1 | a Cordoba, R4 aut |
700 | 1 | a Mendez, GA4 aut |
700 | 1 | a Biernat, MM4 aut |
700 | 1 | a Cornely, OA4 aut |
700 | 1 | a Pagano, L4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Cancersd : MDPI AGg 14:22q 14:22x 2072-6694 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:151274975 |
856 | 4 8 | u https://doi.org/10.3390/cancers14225530 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.